Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
09:44am, Monday, 04'th Nov 2024
Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approval Donidalorsen PDUFA date set for August 21, 2025 Donidalorsen has the potential to be Ionis' sec
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 30'th Oct 2024
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
04:25pm, Wednesday, 23'rd Oct 2024
Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs
Ionis to hold third quarter 2024 financial results webcast
07:05am, Wednesday, 23'rd Oct 2024
Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
AstraZenca drug for nerve damage given EU Green light
02:59am, Monday, 21'st Oct 2024
AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated am
- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo CARLSBAD, Ca
– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , O
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
10:11am, Wednesday, 02'nd Oct 2024
The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
07:00am, Tuesday, 01'st Oct 2024
Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological condition CARLSBAD, Calif. , Oct. 1, 2024 /P
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
01:26pm, Wednesday, 11'th Sep 2024
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Ionis announces pricing of $500.3 million public offering
09:10pm, Monday, 09'th Sep 2024
CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock.
Ionis announces proposed public offering of common stock
04:20pm, Monday, 09'th Sep 2024
CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock.
Ionis to present at upcoming investor conferences
07:05am, Wednesday, 28'th Aug 2024
CARLSBAD, Calif. , Aug. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 20
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
10:16am, Thursday, 15'th Aug 2024
Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.
